147 related articles for article (PubMed ID: 26165625)
1. Contrast-Enhanced Computed Tomography Evaluation of Hepatic Metastases in Breast Cancer Patients Before and After Cytotoxic Chemotherapy or Targeted Therapy.
He H; Cai C; Charnsangavej C; Theriault RL; Green M; Quraishi MA; Yang WT
Can Assoc Radiol J; 2015 Nov; 66(4):356-62. PubMed ID: 26165625
[TBL] [Abstract][Full Text] [Related]
2. Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy.
Mazard T; Assenat E; Dupuy M; Mollevi C; René A; Adenis A; Chauffert B; Boucher E; Francois E; Pierga JY; Ducreux M; Ychou M; Gallix B
Dig Liver Dis; 2019 Aug; 51(8):1185-1191. PubMed ID: 31085108
[TBL] [Abstract][Full Text] [Related]
3. CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations.
Prasad SR; Jhaveri KS; Saini S; Hahn PF; Halpern EF; Sumner JE
Radiology; 2002 Nov; 225(2):416-9. PubMed ID: 12409574
[TBL] [Abstract][Full Text] [Related]
4. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria.
Chung WS; Park MS; Shin SJ; Baek SE; Kim YE; Choi JY; Kim MJ
AJR Am J Roentgenol; 2012 Oct; 199(4):809-15. PubMed ID: 22997372
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of contrast Sonazoid-enhanced ultrasonography for the detection of hepatic metastases in breast cancer.
Mishima M; Toh U; Iwakuma N; Takenaka M; Furukawa M; Akagi Y
Breast Cancer; 2016 Mar; 23(2):231-41. PubMed ID: 25143060
[TBL] [Abstract][Full Text] [Related]
6. Radiofrequency ablation of liver metastases-software-assisted evaluation of the ablation zone in MDCT: tumor-free follow-up versus local recurrent disease.
Keil S; Bruners P; Schiffl K; Sedlmair M; Mühlenbruch G; Günther RW; Das M; Mahnken AH
Cardiovasc Intervent Radiol; 2010 Apr; 33(2):297-306. PubMed ID: 19688366
[TBL] [Abstract][Full Text] [Related]
7. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
[TBL] [Abstract][Full Text] [Related]
8. Non Size Based Morphology Criteria for Assessment of Response in Patients with Liver Metastases of Gastrointestinal Origin Receiving Systemic Treatment.
Alhanafy A; Abdullah MS; Hafez H; Abbas H
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1655-1660. PubMed ID: 29938450
[TBL] [Abstract][Full Text] [Related]
9. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
[TBL] [Abstract][Full Text] [Related]
10. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.
Goshen E; Davidson T; Zwas ST; Aderka D
Technol Cancer Res Treat; 2006 Feb; 5(1):37-43. PubMed ID: 16417400
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
[TBL] [Abstract][Full Text] [Related]
12. Tumor growth kinetics versus RECIST to assess response to locoregional therapy in breast cancer liver metastases.
Seyal AR; Parekh K; Velichko YS; Salem R; Yaghmai V
Acad Radiol; 2014 Aug; 21(8):950-7. PubMed ID: 24833565
[TBL] [Abstract][Full Text] [Related]
13. Prediction of Early Response to Chemotherapy in Breast Cancer Liver Metastases by Diffusion-Weighted MR Imaging.
Bai G; Wang Y; Zhu Y; Guo L
Technol Cancer Res Treat; 2019 Jan; 18():1533033819842944. PubMed ID: 30961445
[TBL] [Abstract][Full Text] [Related]
14. Multidetector computed tomography follow-up of hypoattenuating small liver lesions in patients with rectal cancer.
Tan CH; Bhosale PR; Das P; Crane CH; Viswanathan C; Raval B; Eng C; Iyer RB
Am J Clin Oncol; 2011 Aug; 34(4):411-6. PubMed ID: 20686401
[TBL] [Abstract][Full Text] [Related]
15. Hepatic lesions deemed too small to characterize at CT: prevalence and importance in women with breast cancer.
Khalil HI; Patterson SA; Panicek DM
Radiology; 2005 Jun; 235(3):872-8. PubMed ID: 15833992
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
Gelber RD; Cole BF; Goldhirsch A; Rose C; Fisher B; Osborne CK; Boccardo F; Gray R; Gordon NH; Bengtsson NO; Sevelda P
Lancet; 1996 Apr; 347(9008):1066-71. PubMed ID: 8602056
[TBL] [Abstract][Full Text] [Related]
17. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging.
Buijs M; Kamel IR; Vossen JA; Georgiades CS; Hong K; Geschwind JF
J Vasc Interv Radiol; 2007 Aug; 18(8):957-63. PubMed ID: 17675611
[TBL] [Abstract][Full Text] [Related]
18. CT texture analysis in colorectal liver metastases and the surrounding liver parenchyma and its potential as an imaging biomarker of disease aggressiveness, response and survival.
Beckers RCJ; Trebeschi S; Maas M; Schnerr RS; Sijmons JML; Beets GL; Houwers JB; Beets-Tan RGH; Lambregts DMJ
Eur J Radiol; 2018 May; 102():15-21. PubMed ID: 29685529
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
20. [A long-term survival case of metastatic breast cancer treated with trastuzumab and paclitaxel].
Ogino T; Komoike Y; Ishitobi M; Motomura K; Inaji H; Koyama H
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2234-6. PubMed ID: 19106581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
